This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: Repligen (RGEN), Exelixis (EXEL) and Ocular Therapeutix (OCUL)

Tipranks - Tipranks - Fri Jun 26, 5:56AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Repligen (RGEN), Exelixis (EXEL) and Ocular Therapeutix (OCUL).

TipRanks' Prime Week Sale - 70% Off

Repligen (RGEN)

In a report released yesterday, Matt Hewitt from Craig-Hallum maintained a Buy rating on Repligen. The company’s shares closed last Wednesday at $138.40.

According to TipRanks.com, Hewitt is a 3-star analyst with an average return of 1.1% and a 44.9% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Park Dental Partners, Inc., and Dyadic International. ;'>

Currently, the analyst consensus on Repligen is a Strong Buy with an average price target of $161.27, a 25.8% upside from current levels. In a report issued on June 10, TipRanks – PerPlexity also upgraded the stock to Buy with a $139.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Exelixis (EXEL)

In a report released today, Gregory Renza from Truist Financial initiated coverage with a Hold rating on Exelixis and a price target of $54.00. The company’s shares closed last Wednesday at $52.87.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 17.1% and a 49.9% success rate. Renza covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Perspective Therapeutics, and Abivax SA Sponsored ADR. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Exelixis with a $48.10 average price target, implying a -7.3% downside from current levels. In a report issued on June 22, Morgan Stanley also maintained a Hold rating on the stock with a $50.00 price target.

Ocular Therapeutix (OCUL)

In a report released today, Daniil Gataulin from Chardan Capital maintained a Buy rating on Ocular Therapeutix, with a price target of $23.00. The company’s shares closed last Wednesday at $9.85.

According to TipRanks.com, Gataulin is a 4-star analyst with an average return of 16.2% and a 37.9% success rate. Gataulin covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals, Cognition Therapeutics, and Forte Biosciences. ;'>

Ocular Therapeutix has an analyst consensus of Strong Buy, with a price target consensus of $25.50, which is a 150.7% upside from current levels. In a report issued on June 15, Piper Sandler also maintained a Buy rating on the stock with a $31.00 price target.

Read More on RGEN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).